Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Adjust Predictions for Pactiv Evergreen Following Q4 Results

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Following the release of Pactiv Evergreen’s Q4 results, analysts have adjusted their predictions for the company’s future performance. Baird has raised their price target for Pactiv Evergreen to $15, up from $12, with analyst Ghansham Panjabi maintaining a Neutral rating. Meanwhile, industry experts on Wall Street are forecasting an average price target of $16.58 for Pactiv Evergreen, with a high estimate of $19.00 and a low estimate of $12.50. This represents a 14.58% change from the current price of $14.47. Additionally, Goldman Sachs has increased their price target for Pactiv Evergreen from $12.5 to $14.

PTVE Stock Drops 10.10% on March 4, 2024: Signs of Recovery in Pre-Market Trading

On March 4, 2024, PTVE stock experienced a significant drop in price, decreasing by $1.49 or 10.10% since the market last closed. The stock closed at $13.26, trading near the top of its 52-week range and above its 200-day simple moving average. Despite the drop in price, PTVE has shown some signs of recovery in pre-market trading, rising by $0.40.

The drop in price may be concerning for investors, as it represents a significant decrease in the value of PTVE shares. However, it is important to note that stock prices can be volatile and subject to fluctuations based on various market factors. The fact that PTVE is trading near the top of its 52-week range and above its 200-day simple moving average suggests that the stock has shown strength and resilience in the past.

Investors may want to keep an eye on PTVE stock to see how it performs throughout the day. The rise in pre-market trading could indicate that there is some positive momentum building for the stock. However, it is always important to conduct thorough research and analysis before making any investment decisions.

Overall, the performance of PTVE stock on March 4, 2024, highlights the volatility of the stock market and the importance of staying informed and vigilant as an investor. By staying informed and monitoring market trends, investors can make more informed decisions about their investments.

PTVE Stock Performance Analysis: Revenue and Net Income Decline in 2024

On March 4, 2024, PTVE stock experienced mixed performances based on the financial data provided by CNN Money. The company reported a total revenue of $5.51 billion for the past year, which decreased by 11.41% compared to the previous year. However, the total revenue remained flat at $1.27 billion for the last quarter. In terms of net income, PTVE reported a net loss of $223.00 million for the past year, which represented a significant decrease of 170.13% compared to the previous year. The net income also decreased by 22.22% to $21.00 million for the last quarter. Earnings per share (EPS) for PTVE were reported at -$1.26 for the past year, showing a decrease of 171.4% compared to the previous year. The EPS remained flat at $0.11 for the last quarter. Overall, the financial performance of PTVE on March 4, 2024, reflected a decline in revenue and net income compared to the previous year. The company also reported negative earnings per share, indicating a loss for the past year. Investors may need to closely monitor the company’s financial health and performance in the coming quarters to assess its long-term sustainability and growth potential.

Tags: PTVE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Fintech-online-banks

Galileo Financial Technologies and The Bancorp Partner to Provide RealTime Payment Services

Renewable energy

Analyst Neal Dingmann Bullish on Civitas Resources with Increased Price Target

Finance_Commercial

Analyst Perspectives on Everbridges Price Target

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com